Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Details on Person Anti-MET small tyrosine kinase inhibitors bind MET

Class:Id	Reaction:9735946
_displayName	Anti-MET small tyrosine kinase inhibitors bind MET
_doRelease	TRUE
_timestamp	2021-08-10 14:23:21
authored	[InstanceEdit:9734140] Orlic-Milacic, Marija, 2021-06-15
compartment	[Compartment:876] plasma membrane [Compartment:70101] cytosol
created	[InstanceEdit:9735948] Orlic-Milacic, Marija, 2021-07-06
edited	[InstanceEdit:9750145] Orlic-Milacic, Marija, 2021-08-10
input	[Complex:6806956] HGF:MET dimer [plasma membrane] [Homo sapiens] [CandidateSet:9735962] Anti-MET TKIs [cytosol] [CandidateSet:9735962] Anti-MET TKIs [cytosol]
isChimeric	FALSE
literatureReference	[LiteratureReference:9736224] ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity [LiteratureReference:9736234] Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET [LiteratureReference:9736017] Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance [LiteratureReference:9736183] Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth [LiteratureReference:9736177] Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET [LiteratureReference:9736184] Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib [LiteratureReference:9736137] Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases [LiteratureReference:9736185] Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks [LiteratureReference:9736276] Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models [LiteratureReference:9736134] A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo [LiteratureReference:9736285] SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo [LiteratureReference:9736172] A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase [LiteratureReference:9736281] In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models [LiteratureReference:9736044] Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily [LiteratureReference:9736030] Synergistic activities of MET/RON inhibitor BMS-777607 and mTOR inhibitor AZD8055 to polyploid cells derived from pancreatic cancer and cancer stem cells [LiteratureReference:9736216] A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3 [LiteratureReference:9736055] Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer [LiteratureReference:9736271] Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models [LiteratureReference:9736129] Synthesis, Evaluation, and Mechanism Study of New Tepotinib Derivatives as Antiproliferative Agents [LiteratureReference:9736096] OMO-1 reduces progression and enhances cisplatin efficacy in a 4T1-based non-c-MET addicted intraductal mouse model for triple-negative breast cancer [LiteratureReference:9736261] E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models [LiteratureReference:9736039] MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor [LiteratureReference:9736273] An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms [LiteratureReference:9736260] A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors [LiteratureReference:9734139] Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy [URL:9750163] https://cancerres.aacrjournals.org/content/78/13_Supplement/4791 [LiteratureReference:9750173] Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines
modified	[InstanceEdit:9735980] Orlic-Milacic, Marija, 2021-07-06 [InstanceEdit:9736289] Orlic-Milacic, Marija, 2021-07-06 [InstanceEdit:9736295] Orlic-Milacic, Marija, 2021-07-06 [InstanceEdit:9736301] Orlic-Milacic, Marija, 2021-07-06 [InstanceEdit:9750145] Orlic-Milacic, Marija, 2021-08-10 [InstanceEdit:9750148] Orlic-Milacic, Marija, 2021-08-10 [InstanceEdit:9750149] Orlic-Milacic, Marija, 2021-08-10 [InstanceEdit:9750164] Orlic-Milacic, Marija, 2021-08-10 [InstanceEdit:9750178] Orlic-Milacic, Marija, 2021-08-10 [InstanceEdit:9830342] Matthews, Lisa, 2023-03-08
name	Anti-MET small tyrosine kinase inhibitors bind MET
output	[Complex:9735965] HGF:MET dimer:TKIs [plasma membrane] [Homo sapiens]
releaseDate	2021-09-15
reviewed	[InstanceEdit:9750147] Kadambat Nair, Sisira, 2021-08-05
reviewStatus	[ReviewStatus:9821382] five stars
species	[Species:48887] Homo sapiens
stableIdentifier	[StableIdentifier:9735949] R-HSA-9735946.2
summation	[Summation:9735947] Several tyrosine kinase inhibitors (TKIs) have MET as their ...
(hasEvent)	[Pathway:9734091] Drug-mediated inhibition of MET activation [Homo sapiens]
[Change default viewing format]

No pathways have been reviewed or authored by Anti-MET small tyrosine kinase inhibitors bind MET (9735946)